Table 4.
Reported frequency of NTRK fusion in various types of tumors
| Tumor | Reported frequency | Frequency by TCGA database |
|---|---|---|
| Infantile fibrosarcoma (congenital fibrosarcoma) | 90–100% | 86–91% |
| Secretory breast carcinoma | 80–100% | 92% |
| Mammary analogue secretory carcinoma of the salivary gland | 80–100% | 93–100% |
| Congenital mesoblastic nephroma | 83% | |
| Pediatric high-grade glioma | 40% (< 3 years) | 40% (< 3 years), 5.3%a |
| Melanoma | 16% (Spitzoid tumors) | 0.21% (1/476) |
| Cholangiocarcinoma | 4% | |
| Gastrointestinal stromal tumor (GIST) | 0.5–3% | |
| Inflammatory myofibroblastic tumor (IMT) | 3% | |
| Thyroid cancer | 2% | 2.34% (12/513) |
| Colorectal cancer | 1% | 0.97% (3/310) |
| Sarcoma | 1% | 0.76% (2/263) |
| Head and neck squamous cell carcinoma | < 1% | 0.38% (2/522) |
| Non-small cell carcinoma (NSCLC) | < 1% | 0.18% (1/541) |
| Pancreatic adenocarcinoma | < 1% | 0.56% (1/179) |
| Low-grade glioma | 0.94% (5/534), 2.5% (3/120)a | |
| Glioblastoma multiforme | 0.56% (1/180) | |
| Cervical cancer | 0.33% (1/306) | |
| Breast cancer | 0.18% (2/1119) | |
| Melanoma (pediatric) | 11.11% (1/9)a | |
| B-cell acute lymphoid leukemia | 0.14% (1/716)a |
aData from St. Jude PeCan Data Portal (https://pecan.stjude.cloud/#!/about)